This project focuses on developing a personalized, non-invasive diagnostic method for the early detection of ovarian cancer recurrence using liquid biopsy and digital PCR (dPCR). Ovarian cancer remains one of the most lethal gynecological malignancies due to late diagnosis and high relapse rates. Conventional biochemical markers like CA-125 lack the sensitivity and specificity required for early recurrence detection. Leveraging circulating tumor DNA (ctDNA) and advanced digital PCR, our research aims to create customized assays that track patient-specific somatic mutations identified through whole-exome sequencing (WES) of tumor tissue.

The study will enroll a Saudi cohort and monitor plasma samples longitudinally over a five-year period, validating the sensitivity and clinical utility of the dPCR assay compared to standard tests. This work not only addresses a critical gap in early relapse detection but also contributes to precision medicine by identifying actionable mutations relevant to the Saudi population. The anticipated outcomes include improved patient management, enhanced survival rates, and the establishment of a Saudi-specific ovarian cancer genomics database—aligning directly with Vision 2030’s healthcare goals.

Khawla S Al-Kuraya, Fouad Al-Dayel, Feras Kharrat, Nour Balasan, Khadija Abdulrahman Alobaisi.